Six-Year Ban: Ruti Aga's Case Shows How a Forged Prescription Destroyed a Legitimate Defense

September 10 left a permanent mark on Ruti Aga's career. On that date, the Athletics Integrity Unit (AIU) imposed a six-year ban—two years for the presence of methylprednisolone, and four years for tampering with the investigation through a forged medical prescription. The arithmetic is simple. But the silence around it is not. When I opened this case, the first thing I pulled out was not a stopwatch but a calendar. A half marathon in China was won in March. An anti-doping sample was collected after that race. The sample contained methylprednisolone. The athlete cited a knee injury. The AIU conducted an interview. In that interview, a prescription was produced—allegedly written by a doctor. The investigation found that the clinic did not exist, the "doctor" was a family member with no medical registration, and the prescription was written on an "old pad" from a former clinic that the clinic explicitly disowned. A technical correction is necessary here, because the original reporting called it a "prohibited steroid," which is inaccurate. Methylprednisolone is a glucocorticoid—WADA Prohibited List class S9—not an anabolic steroid (S1). This distinction changes not the arithmetic of the sanction but the possibility of a defense. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral, or rectal routes. A therapeutic knee injection is entirely legal out-of-competition. It becomes a violation only if residues are present in-competition. This technical point is the legal turning point of the entire case. Aga had a legitimate defense pathway available: documentation of the injury, the route and timing of the injection, and a clear explanation of why residues remained in the competition window. With proper medical records, the presence charge could have been argued at the no-fault or no-significant-fault end—potentially a reprimand or a substantial reduction—and the tampering charge would never have existed. But the moment the forged prescription was produced, that defense collapsed. The Code's standard sanction for tampering is four years. The AIU added exactly that. The two years for presence signal that the panel did not find evidence of intentional use—otherwise the sanction could have been higher. But the prescription proved that the athlete attempted concealment. This is a striking paradox: the forgery is itself circumstantial evidence of concealment intent, yet it did not escalate the presence sanction—it merely added a separate and heavier charge. Now the part beyond the original report. Aga is 32. A six-year ban will bring her back at 38—and given the depth of Ethiopian women's marathon running, a 38-year-old returnee with a doping record has essentially zero chance of national selection. I remember her 2026 Tokyo Marathon title, second place in Berlin 2026, three World Marathon Majors podium finishes. These results predate the ban, and the source does not clarify the scope of disqualification. Under standard AIU practice, the result and prize money from the competition where the sample was collected should be annulled—meaning that March half marathon victory, and any ranking points accrued after it. The biggest question in this case, for me, is not why the sanction was six years. The real question is why it came to a forged prescription in the first place. Knee problems are common among marathon runners. Methylprednisolone injections are standard practice in sports medicine. An athlete with a credentialed team doctor applies for a TUE (Therapeutic Use Exemption) or observes WADA's route-specific washout period. In Aga's case, neither happened. Instead, a family member with no medical registration created a prescription on an "old pad." This is not a filing error—it is the signature of an athlete operating without credentialed medical support. A structural pattern emerges here, and I will not connect it to just this one case. In AIU cases emerging from East African road racing, tampering charges now appear repeatedly. The enforcement frontier is shifting from "detection" to "document verification." Aga's case is not an outlier—it belongs to a recognizable category where a fabricated explanation after an initial substance violation makes it heavier. And a note on China's label-race circuit is necessary here. Large appearance-fee budgets, deep East African elite fields, and AIU testing—all three meet in the same race. This circuit has been an attractive, low-risk income tier for East African marathoners between Majors. That same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races. One more thing not in the original report: age. Her personal best of approximately 2:18:34 is recorded from Berlin 2026 (this figure is from my own records, not given in the source). Victory at 2:20:40 in Tokyo 2026. No improvement recorded after that. Meaning the career peaked in 2026-19 and then plateaued. On that plateau, the knee injury arrived, and that same injury opened the door to this entire case. I will not conclude that a six-year ban is unfair or fair. The number matches the arithmetic of the Code. What stops me is that this sanction is for a substance with no proven endurance benefit. That fact will be cited from both sides—as evidence of AIU rigor, and as evidence of disproportionate enforcement against African road runners. The six-year figure is simple. But what remains for Aga after that date—the 2026 Tokyo title, three Major podiums—is a different story. That record still exists, unless the scope of disqualification touches it. And that is the real question that will be settled in the coming months: is this case merely the end of one athlete's career, or the first public audit of the informal medical network in East African road racing that no one noticed? I started this case with a prescription, not a stopwatch. The spreadsheet had forty results, but the story began with a forged document. The data was silent; the prescription spoke.